Design of new anti-viral agents for chronic hepatitis B virus infection.
The effectiveness of therapies for chronic hepatitis B will depend on their ability to inhibit all HBV replicative intermediates including viral SC DNA as well as stimulating the host's immune system to clear virus and produce sustained immunity. Future therapies will require the use of combined treatments in 'cocktail-type arrangements' as outlined in this paper, linked with careful staging of the hepatitis B carrier state.
Locarnini
S
S
Hepatitis Research Unit, Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia.
D000998:Antiviral Agents / Q000627:therapeutic use; D015195:Drug Design; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents